Guillain-Barre Syndrome
43
4
4
17
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.7%
2 terminated out of 43 trials
89.5%
+3.0% vs benchmark
9%
4 trials in Phase 3/4
12%
2 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (43)
Noninvasive Support for Acute Respiratory Failure in Guillain-Barré Syndrome
Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
Ventilator Weaning Practices in Patients Intubated for Guillain-Barré Syndrome or Myasthenia Gravis
Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome
Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome
Ventilator Trigger Sensitivity Adjustment Versus Threshold Inspiratory Muscle Training on Arterial Blood Gases
Biomarkers in Autoimmune Disease of Nervous System
Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology
Prognostic Indicators of Gullian-Barre Syndrome
Predictive Value of Neuromuscular Ultrasound of Cranial Nerves in Guillain-Barré Syndrome
PatientSpot Formerly Known as ArthritisPower
Exploring Accessible Beauty for Individuals With Upper Extremity Deficits
Early and Late Prognosis in Patients With Guillain-Barre Syndrome
Prognosis in Patients With Guillain-Barre Syndrome
Effects of Proprioceptive Neuromuscular Training on Sensory and Motor Function in Guillain Barre Syndrome
RWE-based Treatment Patterns and Outcomes in CIDP
Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil